The purpose of this study is to assess the safety and efficacy of a newly developed psychotherapy for schizotypal personality disorder. This new form of psychotherapy integrates compassion focused therapy and metacognitively oriented psychotherapy.
After being informed about the study and potential risks, all patients giving written informed consent will undergo a psychological assessment so as to determine eligibility for study entry. Patients who meet the eligibility requirements will be randomized in a double-blind manner in a 1:1 ratio to new integrative psychotherapy or treatment as usual (cognitive behavioral therapy plus standard psychopharmacological treatment). One month after the conclusion of the two forms of treatment (both lasting 6 months), patients will have access to the final follow-up assessment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
16
The intervention is a Third Wave Cognitive Therapy targeting metacognitive dysfuctions (through Metacognitively Oriented Psychotherapy) and self-criticism (through Compassion Focused Therapy).
Standard Cognitive Behavioral Therapy for Personality Disorders plus Standard Psychopharmacological Treatment.
Centro di Psicologia e Psicoterapia Tages Onlus - Firenze
Florence, FI, Italy
Change from Baseline Personality Pathology at 8 months
Decrese of Personality Inventory for DSM-5 - Brief Form (PID-5-BF) total score (with a range of 0 to 75; higher scores indicating a more severe psychopathology) from baseline to final assessment after 8 months.
Time frame: 9 measurements over the course of 8 months: (i) at 1 month before intervention starts; (ii) once the treatment starts; (iii) 6 measurements at the end of each month of intervention; iv) at 1-month follow-up.
Schizotypal Personality Disorder Diagnosis (SPD)
Recovery from SPD diagnosis at Module III of Structural Clinical Interview for DSM-5 Alternative Model of Personality Disorders (SCID-5-AMPD).
Time frame: Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment.
General Psychopathology
Decrease of Global Severity Index (with a range of 0 to 4; higher scores indicating a more severe psychopathology) of the Symptom Checklist-90-R (SCL-90-R).
Time frame: Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment.
Metacognition
Increase of Metacognition Assessment Scale - Abreviated (MAS-A) total score (with a range of 0 to 28; higher scores indicating higher metacognitive functioning).
Time frame: Pre-post evaluation between pre-assessment (1-month before the intervention) and 1-month follow-up assessment.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.